Shares of Australian diagnostic firm Genetic Technologies (GENE +33%) are ripping today on the...
Shares of Australian diagnostic firm Genetic Technologies (GENE +33%) are ripping today on the back of a new bullish report issued by Australian investment bank Lodge Partner, starting the shares with a Buy and an aggressive $17 price target (that would make it a four-bagger from current levels). The firm says BREVAGen, GENE's key diagnostic product, is regaining momentum, noting that H2 sales rose 230% over H1, and it expects that trend to continue.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at MarketWatch.com (Sep 25, 2012)
at MarketWatch.com (May 25, 2012)
at MarketWatch.com (May 22, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs